Cardlytics (NASDAQ:CDLX) Price Target Raised to $17.00

Cardlytics (NASDAQ:CDLX - Free Report) had its price target lifted by Needham & Company LLC from $15.00 to $17.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts also recently issued research reports about the stock. Lake Street Capital upped their price target on shares of Cardlytics from $13.00 to $18.00 and gave the company a buy rating in a report on Friday, March 15th. Craig Hallum raised shares of Cardlytics from a hold rating to a buy rating and upped their price target for the company from $10.00 to $18.00 in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus price target of $13.60.

Cardlytics Price Performance

CDLX traded up $0.31 on Tuesday, hitting $14.32. 1,554,927 shares of the company were exchanged, compared to its average volume of 1,637,758. Cardlytics has a fifty-two week low of $4.94 and a fifty-two week high of $20.52. The firm has a market capitalization of $631.66 million, a P/E ratio of -4.31 and a beta of 1.44. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.31 and a current ratio of 1.31. The business's fifty day moving average is $9.77 and its 200 day moving average is $9.74.

Cardlytics (NASDAQ:CDLX - Get Free Report) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. Cardlytics had a negative net margin of 43.56% and a negative return on equity of 25.38%. The business had revenue of $89.17 million during the quarter.

Insider Activity at Cardlytics

In related news, COO Amit Gupta sold 72,658 shares of the company's stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $6.10, for a total transaction of $443,213.80. Following the transaction, the chief operating officer now owns 102,342 shares of the company's stock, valued at $624,286.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Clifford Sosin purchased 311,715 shares of the company's stock in a transaction that occurred on Friday, March 15th. The stock was purchased at an average price of $13.71 per share, with a total value of $4,273,612.65. Following the completion of the transaction, the insider now owns 5,673,676 shares of the company's stock, valued at approximately $77,786,097.96. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Amit Gupta sold 72,658 shares of the company's stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $6.10, for a total transaction of $443,213.80. Following the transaction, the chief operating officer now directly owns 102,342 shares of the company's stock, valued at approximately $624,286.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 102,427 shares of company stock valued at $736,095. Company insiders own 0.78% of the company's stock.

Hedge Funds Weigh In On Cardlytics

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC increased its position in Cardlytics by 238.4% during the second quarter. FMR LLC now owns 1,428 shares of the company's stock worth $32,000 after purchasing an additional 1,006 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in Cardlytics during the second quarter worth approximately $38,000. Tower Research Capital LLC TRC increased its position in Cardlytics by 186.5% during the third quarter. Tower Research Capital LLC TRC now owns 2,137 shares of the company's stock worth $35,000 after purchasing an additional 1,391 shares during the last quarter. Comerica Bank acquired a new stake in shares of Cardlytics in the third quarter worth $40,000. Finally, Hsbc Holdings PLC increased its position in shares of Cardlytics by 41.2% in the first quarter. Hsbc Holdings PLC now owns 5,149 shares of the company's stock worth $287,000 after acquiring an additional 1,503 shares in the last quarter. Institutional investors and hedge funds own 68.10% of the company's stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.